Description du projet
Impression d’organes en 3D pour la médecine régénérative du foie
Les maladies hépatiques sont à l’origine de deux millions de décès dans le monde chaque année. Alors que la transplantation hépatique est le moyen le plus efficace de restaurer les fonctions normales dans plusieurs pathologies, y compris l’insuffisance hépatique aiguë ou les tumeurs malignes du foie, moins de 10 % des besoins de transplantation sont satisfaits au niveau mondial. Le projet ORGANTRANS, financé par l’UE, vise à remplacer la transplantation hépatique chez les patients atteints d’insuffisance hépatique en phase terminale grâce au développement d’une plateforme d’impression 3D de tissus hépatiques. Le projet couvrira l’ensemble du cycle de développement, de la source cellulaire et l’ingénierie tissulaire aux essais permettant une adoption rapide de ses résultats en pratique clinique. Il est important de noter que cette recherche créera de nouvelles technologies applicables à d’autres systèmes d’organes en médecine régénérative.
Objectif
End-stage liver failure is a major healthcare challenge. Liver diseases account for approximately 2 million deaths per year worldwide. Liver transplantation is the most effective way to re-establish a liver with normal functions for various diseases including acute liver failure or liver malignancies. Currently, less than 10% of global transplantation needs are met and the gap between patients on transplant waiting lists and available donor organs is steadily increasing.
ORGANTRANS proposes a disruptive alternative to donor organs for patients with chronic or end-stage liver diseases who have still to isolate autologous liver stem cells. Driven by a need of leading European transplant centers, ORGANTRANS will tackle current obstacles for liver regenerative medicine by combining advanced know-how in cell biology, biomaterials, bioengineering, automation, standardization and clinical translation.
ORGANTRANS will develop a liver tissue printing platform that will be shortly deployed under the “compassionate use exemption” by three leading European transplant centers belonging to the consortium or the External Advisory Board. ORGANTRANS will not only deliver an ATMP, but also platform technologies that can be scaled to other organ systems, as organoid technology is one of the largest parts of regenerative medicine. The project covers the entire value chain (from cell source, tissue engineering, bioprinting, post-processing to testing) allowing for early adoption of its results (product & process) in clinical practice. The platform will first be scaled to Europe and then to the rest of the world.
Champ scientifique
- natural sciencesbiological sciencescell biology
- medical and health sciencesmedical biotechnologytissue engineering
- medical and health sciencesmedical biotechnologycells technologiesstem cells
- medical and health sciencesclinical medicinehepatology
- medical and health sciencesclinical medicinetransplantation
Mots‑clés
Programme(s)
Régime de financement
RIA - Research and Innovation actionCoordinateur
2000 Neuchatel
Suisse